Significant PFS Improvement with Ibrutinib-Rituximab Compared to Immunochemotherapy in Previously Untreated Patients with Mantle Cell Lymphoma By Ogkologos - October 24, 2025 231 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ENRICH study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR EMA Recommends Granting a Marketing Authorisation for Poherdy April 10, 2026 How to Get More Support From Your Oncology Pharmacist During Cancer February 24, 2021 Biweekly Cabazitaxel in Patients 65 Years or Older with mCRPC for... November 7, 2023 People with Intellectual Disability at Increased Risk of Cancer September 21, 2021 Load more HOT NEWS ¿Las píldoras anticonceptivas afectan mi riesgo de cáncer? Restaurant Opens Early For A 3-Year-Old Girl With Leukemia So She... 2022 ASCO Annual Meeting: Social Services Spending and Cancer Survival, Clinical... Factors Associated with COVID-19 Severity Among Patients with Cancer
